Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Chair Christopher C Butler, Jienchi Dorward, Ly-Mee Yu, Oghenekome Gbinigie, F D Gail Hayward, Benjamin R Saville, Oliver Van Hecke, Nick Berry, Michelle Detry, Christina Saunders, Mark Fitzgerald, Victoria Harris, Mahendra G Patel, Simon De Lusignan, Emma Ogburn, Philip H Evans, Nicholas Pb Thomas, Fd Richard Hobbs
The Lancet, doi:10.1016/s0140-6736(21)00461-x
Background Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community who had an increased risk of complications.
Methods In this UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial of interventions against COVID-19 in people at increased risk of an adverse clinical course (PRINCIPLE), we randomly assigned people aged 65 years and older, or 50 years and older with at least one comorbidity, who had been unwell for 14 days or less with suspected COVID-19, to usual care plus azithromycin 500 mg daily for three days, usual care plus other interventions, or usual care alone. The trial had two coprimary endpoints measured within 28 days from randomisation: time to first self-reported recovery, analysed using a Bayesian piecewise exponential, and hospital admission or death related to COVID-19, analysed using a Bayesian logistic regression model. Eligible participants with outcome data were included in the primary analysis, and those who received the allocated treatment were included in the safety analysis. The trial is registered with ISRCTN, ISRCTN86534580. Findings The first participant was recruited to PRINCIPLE on April 2, 2020. The azithromycin group enrolled participants between May 22 and Nov 30, 2020, by which time 2265 participants had been randomly assigned, 540 to azithromycin plus usual care, 875 to usual care alone, and 850 to other interventions. 2120 (94%) of 2265 participants provided follow-up data and were included in the Bayesian primary analysis, 500 participants in the azithromycin plus usual care group, 823 in the usual care alone group, and 797 in other intervention groups. 402 (80%) of 500 participants in the azithromycin plus usual care group and 631 (77%) of 823 participants in the usual care alone group reported feeling recovered within 28 days. We found little evidence of a meaningful benefit in the azithromycin plus usual care group in time to first reported recovery versus usual care alone (hazard ratio 1•08, 95% Bayesian credibility interval [BCI] 0•95 to 1•23), equating to an estimated benefit in median time to first recovery of 0•94 days (95% BCI -0•56 to 2•43). The probability that there was a clinically meaningful benefit of at least 1•5 days in time to recovery was 0•23. 16 (3%) of 500 participants in the azithromycin plus usual care group and 28 (3%) of 823 participants in the usual care alone group were hospitalised (absolute benefit in percentage 0•3%, 95% BCI -1•7 to 2•2). There were no deaths in either study group. Safety outcomes were similar in both groups. Two (1%) of 455 participants in the azothromycin plus usual care group and four (1%) of 668 participants in the usual care alone group reported admission to hospital during the trial, not related to..
References
Abaleke, Abbas, Abbasi, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19-final report, N Engl J Med
Boulware, Pullen, Bangdiwala, A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19, N Engl J Med
Coutard, Valle, De Lamballerie, Canard, Seidah et al., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral Res
De Lusignan, Dorward, Correa, Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study, Lancet Infect Dis
De Lusignan, Jones, Dorward, The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: protocol to develop extended COVID-19 surveillance and trial platforms, JMIR Public Health Surveill
Furtado, Berwanger, Fonseca, Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial, Lancet
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Joy, Hobbs, Bernal, Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England, Br J Gen Pract
Kim, Read, Fauci, Therapy for early COVID-19: a critical need, JAMA
Langford, So, Raybardhan, Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clin Microbiol Infect
Little, Stuart, Moore, Amoxicillin for acute lowerrespiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial, Lancet Infect Dis
Million, Lagier, Gautret, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Men Infect Dis
Min, Jang, Macrolide therapy in respiratory viral infections, Mediators Inflamm
Moustgaard, Clayton, Jones, Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study, BMJ
Poschet, Perkett, Timmins, Deretic, Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells, bioRxiv,
doi:10.1101/2020.03.29.008631Skipper, Pastick, Engen, Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial, Ann Intern Med
Sudre, Murray, Varsavsky, Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App, medRxiv,
doi:10.1101/2020.10.19.20214494(preprintTopp, Østergaard, Søndergaard, Bech, The WHO-5 Well-Being Index: a systematic review of the literature, Psychother Psychosom
Touret, Gilles, Barral, In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep
Woodcock, Lavange, Master protocols to study multiple therapies, multiple diseases, or both, N Engl J Med
{ 'indexed': {'date-parts': [[2022, 1, 21]], 'date-time': '2022-01-21T01:49:19Z', 'timestamp': 1642729759939},
'reference-count': 26,
'publisher': 'Elsevier BV',
'issue': '10279',
'license': [ { 'start': { 'date-parts': [[2021, 3, 1]],
'date-time': '2021-03-01T00:00:00Z',
'timestamp': 1614556800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2021, 2, 18]],
'date-time': '2021-02-18T00:00:00Z',
'timestamp': 1613606400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'funder': [ {'DOI': '10.13039/501100000272', 'name': 'NIHR', 'doi-asserted-by': 'publisher'},
{'DOI': '10.13039/100010269', 'name': 'Wellcome Trust', 'doi-asserted-by': 'publisher'}],
'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.fr', 'thelancet.com', 'em-consulte.com', 'elsevier.com',
'sciencedirect.com'],
'crossmark-restriction': True},
'short-container-title': ['The Lancet'],
'published-print': {'date-parts': [[2021, 3]]},
'DOI': '10.1016/s0140-6736(21)00461-x',
'type': 'journal-article',
'created': {'date-parts': [[2021, 3, 5]], 'date-time': '2021-03-05T19:12:14Z', 'timestamp': 1614971534000},
'page': '1063-1074',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 76,
'title': [ 'Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an '
'adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive '
'platform trial'],
'prefix': '10.1016',
'volume': '397',
'author': [ {'given': 'Christopher C', 'family': 'Butler', 'sequence': 'first', 'affiliation': []},
{'given': 'Jienchi', 'family': 'Dorward', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ly-Mee', 'family': 'Yu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Oghenekome', 'family': 'Gbinigie', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gail', 'family': 'Hayward', 'sequence': 'additional', 'affiliation': []},
{'given': 'Benjamin R', 'family': 'Saville', 'sequence': 'additional', 'affiliation': []},
{'given': 'Oliver', 'family': 'Van Hecke', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nick', 'family': 'Berry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Michelle', 'family': 'Detry', 'sequence': 'additional', 'affiliation': []},
{'given': 'Christina', 'family': 'Saunders', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mark', 'family': 'Fitzgerald', 'sequence': 'additional', 'affiliation': []},
{'given': 'Victoria', 'family': 'Harris', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mahendra G', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Simon', 'family': 'de Lusignan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Emma', 'family': 'Ogburn', 'sequence': 'additional', 'affiliation': []},
{'given': 'Philip H', 'family': 'Evans', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nicholas PB', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []},
{'given': 'FD Richard', 'family': 'Hobbs', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/S0140-6736(21)00461-X_bib1',
'doi-asserted-by': 'crossref',
'first-page': '2149',
'DOI': '10.1001/jama.2020.22813',
'article-title': 'Therapy for early COVID-19: a critical need',
'volume': '324',
'author': 'Kim',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib2',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/s41598-020-70143-6',
'article-title': 'In vitro screening of a FDA approved chemical library reveals potential '
'inhibitors of SARS-CoV-2 replication',
'volume': '10',
'author': 'Touret',
'year': '2020',
'journal-title': 'Sci Rep'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib3',
'article-title': 'Azithromycin in viral infections',
'author': 'Oliver',
'year': '2020',
'journal-title': 'Rev Med Virol'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib4',
'article-title': 'Azithromycin and ciprofloxacin have a chloroquine-like effect on '
'respiratory epithelial cells',
'author': 'Poschet',
'year': '2020',
'journal-title': 'bioRxiv'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib5',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2020.104742',
'article-title': 'The spike glycoprotein of the new coronavirus 2019-nCoV contains a '
'furin-like cleavage site absent in CoV of the same clade',
'volume': '176',
'author': 'Coutard',
'year': '2020',
'journal-title': 'Antiviral Res'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib6',
'doi-asserted-by': 'crossref',
'DOI': '10.1155/2012/649570',
'article-title': 'Macrolide therapy in respiratory viral infections',
'volume': '2012',
'author': 'Min',
'year': '2012',
'journal-title': 'Mediators Inflamm'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib7',
'article-title': 'PRINCIPLE trial demonstrates scope for in-pandemic improvement in '
'primary care antibiotic stewardship',
'author': 'de Lusignan',
'year': '2021',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib8',
'doi-asserted-by': 'crossref',
'first-page': '779',
'DOI': '10.1038/s41564-020-0739-4',
'article-title': 'Antimicrobial resistance in the age of COVID-19',
'volume': '5',
'year': '2020',
'journal-title': 'Nat Microbiol'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib9',
'doi-asserted-by': 'crossref',
'first-page': '605',
'DOI': '10.1016/S0140-6736(21)00149-5',
'article-title': 'Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): '
'a randomised, controlled, open-label, platform trial',
'volume': '397',
'author': 'Abaleke',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib10',
'doi-asserted-by': 'crossref',
'first-page': '2041',
'DOI': '10.1056/NEJMoa2019014',
'article-title': 'Hydroxychloroquine with or without azithromycin in mild-to-moderate '
'Covid-19',
'volume': '383',
'author': 'Cavalcanti',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib11',
'doi-asserted-by': 'crossref',
'first-page': '959',
'DOI': '10.1016/S0140-6736(20)31862-6',
'article-title': 'Azithromycin in addition to standard of care versus standard of care '
'alone in the treatment of patients admitted to the hospital with severe '
'COVID-19 in Brazil (COALITION II): a randomised clinical trial',
'volume': '396',
'author': 'Furtado',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib12',
'doi-asserted-by': 'crossref',
'first-page': '62',
'DOI': '10.1056/NEJMra1510062',
'article-title': 'Master protocols to study multiple therapies, multiple diseases, or '
'both',
'volume': '377',
'author': 'Woodcock',
'year': '2017',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib15',
'doi-asserted-by': 'crossref',
'first-page': '1034',
'DOI': '10.1016/S1473-3099(20)30371-6',
'article-title': 'Risk factors for SARS-CoV-2 among patients in the Oxford Royal College '
'of General Practitioners Research and Surveillance Centre primary care '
'network: a cross-sectional study',
'volume': '20',
'author': 'de Lusignan',
'year': '2020',
'journal-title': 'Lancet Infect Dis'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib18',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2020.105949',
'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results '
'of an open-label non-randomized clinical trial',
'volume': '56',
'author': 'Gautret',
'year': '2020',
'journal-title': 'Int J Antimicrob Agents'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib19',
'doi-asserted-by': 'crossref',
'first-page': '517',
'DOI': '10.1056/NEJMoa2016638',
'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis '
'for Covid-19',
'volume': '383',
'author': 'Boulware',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib20',
'doi-asserted-by': 'crossref',
'first-page': '623',
'DOI': '10.7326/M20-4207',
'article-title': 'Hydroxychloroquine in nonhospitalized adults with early COVID-19 : a '
'randomized trial',
'volume': '173',
'author': 'Skipper',
'year': '2020',
'journal-title': 'Ann Intern Med'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib21',
'doi-asserted-by': 'crossref',
'first-page': '1813',
'DOI': '10.1056/NEJMoa2007764',
'article-title': 'Remdesivir for the treatment of Covid-19—final report',
'volume': '383',
'author': 'Beigel',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib22',
'doi-asserted-by': 'crossref',
'DOI': '10.2196/19773',
'article-title': 'The Oxford Royal College of General Practitioners Clinical Informatics '
'Digital Hub: protocol to develop extended COVID-19 surveillance and '
'trial platforms',
'volume': '6',
'author': 'de Lusignan',
'year': '2020',
'journal-title': 'JMIR Public Health Surveill'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib24',
'doi-asserted-by': 'crossref',
'first-page': '167',
'DOI': '10.1159/000376585',
'article-title': 'The WHO-5 Well-Being Index: a systematic review of the literature',
'volume': '84',
'author': 'Topp',
'year': '2015',
'journal-title': 'Psychother Psychosom'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib25',
'doi-asserted-by': 'crossref',
'first-page': '123',
'DOI': '10.1016/S1473-3099(12)70300-6',
'article-title': 'Amoxicillin for acute lower-respiratory-tract infection in primary care '
'when pneumonia is not suspected: a 12-country, randomised, '
'placebo-controlled trial',
'volume': '13',
'author': 'Little',
'year': '2013',
'journal-title': 'Lancet Infect Dis'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib26',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.tmaid.2020.101663',
'article-title': 'Clinical and microbiological effect of a combination of '
'hydroxychloroquine and azithromycin in 80 COVID-19 patients with at '
'least a six-day follow up: a pilot observational study',
'volume': '34',
'author': 'Gautret',
'year': '2020',
'journal-title': 'Travel Med Infect Dis'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib27',
'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and '
'azithromycin: a retrospective analysis of 1061 cases in Marseille, '
'France',
'volume': '35',
'author': 'Million',
'year': '2020',
'journal-title': 'Travel Men Infect Dis'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib28',
'doi-asserted-by': 'crossref',
'first-page': '1622',
'DOI': '10.1016/j.cmi.2020.07.016',
'article-title': 'Bacterial co-infection and secondary infection in patients with '
'COVID-19: a living rapid review and meta-analysis',
'volume': '26',
'author': 'Langford',
'year': '2020',
'journal-title': 'Clin Microbiol Infect'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib30',
'article-title': 'Attributes and predictors of long-COVID: analysis of COVID cases and '
'their symptoms collected by the Covid Symptoms Study App',
'author': 'Sudre',
'year': '2020',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib31',
'doi-asserted-by': 'crossref',
'first-page': 'e890',
'DOI': '10.3399/bjgp20X713393',
'article-title': 'Excess mortality in the first COVID pandemic peak: cross-sectional '
'analyses of the impact of age, sex, ethnicity, household size, and '
'long-term conditions in people of known SARS-CoV-2 status in England',
'volume': '70',
'author': 'Joy',
'year': '2020',
'journal-title': 'Br J Gen Pract'},
{ 'key': '10.1016/S0140-6736(21)00461-X_bib32',
'article-title': 'Impact of blinding on estimated treatment effects in randomised '
'clinical trials: meta-epidemiological study',
'volume': '368',
'author': 'Moustgaard',
'year': '2020',
'journal-title': 'BMJ'}],
'container-title': ['The Lancet'],
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S014067362100461X?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S014067362100461X?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 3, 25]],
'date-time': '2021-03-25T06:05:34Z',
'timestamp': 1616652334000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 3]]},
'references-count': 26,
'journal-issue': {'issue': '10279', 'published-print': {'date-parts': [[2021, 3]]}},
'alternative-id': ['S014067362100461X'],
'URL': 'http://dx.doi.org/10.1016/s0140-6736(21)00461-x',
'relation': {},
'ISSN': ['0140-6736'],
'issn-type': [{'value': '0140-6736', 'type': 'print'}],
'subject': ['General Medicine'],
'published': {'date-parts': [[2021, 3]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Azithromycin for community treatment of suspected COVID-19 in people at '
'increased risk of an adverse clinical course in the UK (PRINCIPLE): a '
'randomised, controlled, open-label, adaptive platform trial',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'The Lancet', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/S0140-6736(21)00461-X',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{ 'value': 'https://doi.org/10.1016/S0140-6736(21)00661-9',
'name': 'associatedlink',
'label': 'CrossRef DOI link to the associated document'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 The Author(s). Published by Elsevier Ltd.',
'name': 'copyright',
'label': 'Copyright'}]}
